Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Interleukin-2 (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2017.
- 12 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2017.
- 22 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.